Skip to content
TrialScanner

NCT04596150

Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

Phase 2CompletedCTMXLead

Registry record

Lead sponsor
CytomX Therapeutics
Conditions
Neoplasms; Breast Neoplasms; Breast Neoplasms, Triple-Negative; Breast Cancer; Breast Neoplasms, Hormone Receptor Positive/HER2 Negative
Primary completion
Jun 2, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04596150 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04596150: Study to Evaluate the Safety... | TrialScanner